# Scott Horner

> Scott Horner is a seed investor at Middleland Capital backing Medical and Life Science. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Middleland Capital](https://shizune.co/investors/profile/middleland-capital)
- Location: Washington, United States
- Total investments: 1
- Last investment: Aug 2022
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/scott-horner-5942104

Scott Horner is a seed investor at Middleland Capital in Washington focused on Medical and Life Science. Scott is a Managing Director at Middleland Capital where he is responsible for portfolio management and evaluating investment opportunities in agriculture and biotechnology. Scott currently sits on the Board of Directors of Mycotechnology Inc., Plant Response Biotech, and Blue Prairie Brands, and is a Board observer on Advanced AnimalDiagnostics, Vive Crop Protection, ZeaKal, and Virgin Plants Inc. Prior to joining Middleland, Scott was a Managing Director at Third Security, LLC, where he was responsible for assessing potential investments in the biotechnology and pharmaceutical sectors. He also worked with many portfolio companies of Third Security’s managed investment funds providing business intelligence and operational support, and served on the Board of Directors of Synchrony Inc. (acquired by Dresser-Rand Corp.). In addition to portfolio management duties, he also took on interim operating roles within several portfolio companies, including President and Chief Executive Officer of Pinnacle Pharmaceuticals, VP Chemistry, Intrexon Corporation (NYSE:XON) and VP Business Development, Intrexon Corporation. Prior to joining Third Security, he was a founder and Chief Scientific Officer at Pathologics, LLC, a point of care diagnostics company located in Rochester, NY. Scott received his Ph.D. in Bioorganic Chemistry and an M.S. in Biophysics from the University of Rochester and a B.S. in Biochemistry from the State University of New York at Albany.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Life Science | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ordaos Bio | Ordaōs is a human-enabled, machine-driven drug design company. We create customized mini-proteins that help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods. miniPRO proteins are created and evaluated in silico, and then rigorously tested invitro, which enables us to reliably and repeatedly deliver de novo solutions that meet our client’s stringent requirements at scale, including novelty and probability of clinical success. At Ordaōs, we help birth novel therapies that reduce patient suffering, improve health, and extend life. | $5M | Seed | Aug 25, 2022 |  |

1 of 1 investments shown.

## Co-investors
- [Banyan Pacific](https://shizune.co/investors/profile/banyan-pacific) — VC Fund, 1 deal together
- [Citta Capital](https://shizune.co/investors/profile/citta-capital) — VC Fund, 1 deal together
- [IAG Capital Partners](https://shizune.co/investors/profile/iag-capital-partners) — VC Fund, 1 deal together
- [Route 66 Ventures](https://shizune.co/investors/profile/route-66-ventures) — VC Fund, 1 deal together

## About Middleland Capital

VC Fund · Washington, United States

Middleland Capital is a private investment firm focused on global early-stage technology opportunities. Leveraging a unique breadth of geographic and industry experience, the firm seeks partnerships with exceptional management teams to commercialize innovative technologies, accelerate growth, and build long-term value around the world.

5 contacts available at Middleland Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Alexander Pessala | Principal | https://shizune.co/investors/profile/alexander-pessala |
| David P. Mixer | Managing Partner | https://shizune.co/investors/profile/david-p-mixer |
| Scott Horner | Managing Director & Co-Founder | https://shizune.co/investors/profile/scott-horner |
| Severine Balick | Partner & Co-Founder | https://shizune.co/investors/profile/severine-balick |
| Brian Mixer | Managing Director, Co-Founder & Partner | https://shizune.co/investors/profile/brian-mixer |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Scott Horner invest in?

Scott Horner invests primarily in Medical, Life Science and Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Scott Horner last invest?

The most recent investment recorded for Scott Horner closed in Aug 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co